Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

533.14 -20.01 (-3.62%)
Delayed Quote Updated: 2:49 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
78 79 Next >
News headline image
Vertex: 3 Key Takeaways for Long-Term Investors ↗
Vertex is betting on nephrology and rare endocrinology to build a fifth and fourth commercial pillar beyond cystic fibrosis. 
Via The Motley Fool
Topics Earnings
News headline image
Vertex (VRTX) Q3 2026 Earnings Call Transcript ↗
Revenue grew 12% as newer products like CASGEVY and JOURNAVX ramped up significantly. 
Via The Motley Fool
Topics Earnings
News headline image
VRTX Q3 deep dive: Pipeline, product launches, and Crinetics integration shape outlook
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 11.8% year on year t... 
Via StockStory
Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 Earnings: In-Line Revenue, Modest EPS Miss, Raised Guidance and Higher Spending ↗
Via Chartmill
News headline image
Vertex Pharmaceuticals Q3 Earnings Call Highlights ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) reported third-quarter 2026 revenue growth of 12% year over year, supported by continued cystic fibrosis franchise growth and contributions from newer products... 
Via MarketBeat
Topics Earnings
News headline image
Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reaction ↗
Vertex's cystic fibrosis business is still growing, but the company is pouring those gains into new franchises. Here's what the third quarter shows about the cost of building its next act. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q3 2026 sales top estimates
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 11.8% year on year... 
Via StockStory
News headline image
Vertex Reports Third Quarter 2026 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Pharmaceuticals earnings: what to look for from VRTX
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market close. Here’s what to expect. Vertex Pharma... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 large-cap stocks with solid fundamentals
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m... 
Via StockStory
After-Hours S&P 500 Movers: Mondelez and FedEx Freight Gain, Intel and Reddit Fall ↗
Via Chartmill
Topics Stocks
News headline image
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue ↗
Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory. 
Via The Motley Fool
Topics Intellectual Property Lawsuit
News headline image
I'm Not Worried About a Stock Market Crash, and It's Because I'm Making This 1 Investing Move ↗
Here's how I'm staying calm as valuations hit record highs. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More ↗
The company's gene-editing-focused platform looks promising. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change. ↗
Vertex is expanding beyond its cystic fibrosis franchise. 
Via The Motley Fool
News headline image
Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy... 
Via MarketBeat
News headline image
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026
From Vertex Pharmaceuticals Incorporated
Via Business Wire
S&P 500 Premarket Movers on Oct. 21: Tech Hardware and AI Suppliers Gain, Health Care Declines ↗
Via Chartmill
Topics Artificial Intelligence Stocks Supply Chain
News headline image
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Vertex Appoints Daniel Brennan to its Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It ↗
Buffett has warned about "gambling" in the market. 
Via The Motley Fool
Topics Intellectual Property Retirement
News headline image
Where Will CRISPR Therapeutics Stock Be in 2030? ↗
The company's expertise in gene editing could lead to more breakthroughs. 
Via The Motley Fool
News headline image
Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock. ↗
Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, Oct. 12. 
Via The Motley Fool
Topics ETFs
News headline image
1 Nasdaq 100 Stock on Our Watchlist and 2 That Underwhelm
The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like ... 
Via StockStory
News headline image
Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders ↗
Vertex Pharmaceuticals is showing that it isn't a one-trick pony. 
Via The Motley Fool
News headline image
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA hurdle with an expanding oncology pipeline behind it. 
Via The Motley Fool
News headline image
2 High-Flying Stocks on Our Watchlist and 1 We Question
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ... 
Via StockStory
News headline image
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right. ↗
Most of any gains (or lack thereof) from here will be driven by just three factors. 
Via The Motley Fool
News headline image
Vertex to Announce Third Quarter 2026 Financial Results November 2nd
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
78 79 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.